For IHC-Fr: Use at a concentration of 10 μg/ml. For IHC-P: Use at a concentration of 10 μg/ml. For IP: Use at an assay dependent dilution. For WB: Use at a concentration of 5 μg/ml. Optimal dilutions/concentrations should be determined by the researcher.
SW480, Y1 cells, or normal skin tissue
This antibody reacts with cK Ras and vK Ras, and cross-reacts with cH Ras or cN Ras p21s in immunoblotting. For this reason we recommend a sample concentration step prior to immunoblotting; concentrate to 5 μg/ml with 1% gelatin as a stabilizer. For immunoprecipitation, use 5 μg per sample with 45 μl protein A agarose.
50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5, containing 0.09% sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.
0.1 mg/ml (Please refer to the vial label for the specific concentration.)
Recombinant fragment, corresponding to C terminal amino acids 54-189 of Rat cK RAS.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Kras Proto-Oncogene, Gtpase,C-K-Ras,Cfc2,K-Ras2A,K-Ras2B,K-Ras4A,K-Ras4B,K-Ras,Ki-Ras,Kras1,Kras2,Ns,Ns3,Rald,Rask2,C-Ki-Ras2,Kras
This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]